GOSS Logo

Gossamer Bio, Inc. (GOSS) 

NASDAQ
Market Cap
$157.63M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
165 of 774
Rank in Industry
101 of 433

Largest Insider Buys in Sector

GOSS Stock Price History Chart

GOSS Stock Performance

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel …

Insider Activity of Gossamer Bio, Inc.

Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $324,442 and sold $53,578 worth of Gossamer Bio, Inc. stock.

On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $969,539 and sold $356,034 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $1M. Giraudo Bryan (COO/CFO) — $118,220. Smith Robert Paul JR (Chief Commercial Officer) — $15,050.

The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.

List of Insider Buy and Sell Transactions, Gossamer Bio, Inc.

2024-06-24SaleChief Medical Officer
1,908
0.0007%
$0.66$1,260+11.46%
2024-06-21PurchasePresident & CEO
372,000
0.2168%
$0.67$250,282+41.62%
2024-06-18PurchaseCOO/CFO
100,000
0.0512%
$0.59$59,110+68.57%
2024-06-17PurchaseChief Commercial Officer
25,000
0.013%
$0.60$15,050+75.75%
2024-03-27SaleEVP, Tech Ops and Admin
6,430
0.0028%
$1.16$7,430-24.97%
2024-03-27SalePresident & CEO
23,172
0.0101%
$1.16$26,773-24.97%
2024-03-27SaleCOO/CFO
6,430
0.0028%
$1.16$7,431-24.97%
2024-03-18SaleChief Medical Officer
4,018
0.0017%
$1.33$5,342-35.77%
2024-03-18SaleEVP, Regulatory Affairs
4,018
0.0017%
$1.33$5,343-35.77%
2023-11-15Purchasedirector
32,000
0.0139%
$0.79$25,213+11.11%
2023-11-13PurchaseCOO/CFO
200,000
0.0795%
$0.56$112,880+40.06%
2023-06-22SaleChief Medical Officer
1,814
0.0018%
$1.29$2,340-34.29%
2023-04-04PurchaseCOO/CFO
55,000
0.0583%
$1.02$56,095+3.45%
2023-03-16SaleChief Medical Officer
7,563
0.0083%
$1.10$8,3040.00%
2023-03-16SaleChief Scientific Officer
6,029
0.0066%
$1.10$6,6200.00%
2023-03-16SaleEVP, Regulatory Affairs
7,564
0.0083%
$1.10$8,3050.00%
2022-10-24SaleChief Medical Officer
4,757
0.0056%
$12.07$57,431-88.94%
2022-10-24SaleChief Scientific Officer
4,876
0.0058%
$12.07$58,868-88.94%
2022-10-24SaleEVP, Regulatory Affairs
4,757
0.0056%
$12.07$57,431-88.94%
2022-07-15PurchasePresident & CEO
138,696
0.099%
$7.21$999,998-79.92%

Insider Historical Profitability

<0.0001%
Hasnain FaheemPresident & CEO
5408073
2.3866%
$0.7042<0.0001%
Christian WaageEVP, Tech Ops and Admin
585934
0.2586%
$0.7043<0.0001%
Giraudo BryanCOO/CFO
480010
0.2118%
$0.7093<0.0001%
Smith Robert Paul JRChief Commercial Officer
25000
0.011%
$0.7010
Gujrathi SheilaPresident & CEO
4048242
1.7865%
$0.7010<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Nea Management Company Llc$18.69M715.84M0%+$00.09
Artal Group S A$15.7M5.8813.31M+10.37%+$1.47M0.07
The Vanguard Group$13.88M5.211.76M+1.1%+$151,217.00<0.0001
Ecor1 Capital Llc$10.85M4.079.2M0%+$00.08
Octagon Capital Advisors LP$10.84M4.069.19M0%+$00.06
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.